Research areas

Line Planck Kongstad is Associate Professor and Senior Health Economist at the Danish Centre for Health Economics (DaCHE), Department of Public Health, University of Southern Denmark. She holds an MSc in Economics (2011) and a PhD in Economics (2014) from the University of Southern Denmark. 

Her research focuses on health economic evaluation and the use of economic evidence to inform healthcare decision-making and priority setting. She has extensive experience in trial-based economic evaluation, including the use of Danish register data, costing studies, and analyses of health outcomes and resource use. Her recent research increasingly involves decision-analytic modelling and distributional cost-effectiveness analysis to assess the long-term health, economic, and equity impacts of health interventions. 

Line leads and contributes to health economic work packages in large interdisciplinary research programmes spanning obesity, diabetes, cardiovascular disease, public health, and regenerative medicine. Her work combines methodological health economics with applied research and close collaboration with clinicians, public health researchers, and healthcare stakeholders. 

She is currently involved in several major research projects. In BLOOM, a cluster-randomised trial promoting healthy weight development in early childhood, she leads the health economic work package. In LightCOM, a large clinical trial of obesity treatment, she is responsible for the within-trial health economic evaluation. In STEAM, a collaboration between several Danish Steno Diabetes Centers, she contributes to the development and application of diabetes simulation models for health economic evaluation. She is also the health economist in STEMBRACE, a multidisciplinary consortium within regenerative medicine and stem cell research, where she investigates the economic and societal implications of emerging stem cell-based therapies. 

Her research aims to generate robust and policy-relevant evidence on the costs, effects, and equity implications of health interventions and to strengthen the integration of health economics into interdisciplinary clinical, public health, and regenerative medicine research. She has also contributed to introducing distributional cost-effectiveness analysis in Danish research collaborations and to establishing health economic.